REGENXBIO INC. overview

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY PR Newswire ROCKVILLE, Md., March 19, 2025 Positive biomarker data in patient aged 1-3 add to consistent, robust microdystrophin and transduction levels across all treated ages Patient aged 3 years at dosing had expression level at 122.3% compared to control With a differentiated novel construct and proactive short course immune modulation regimen, RGX-202 continues to demonstrate encouraging safety...

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates PR Newswire ROCKVILLE, Md., March 13, 2025 Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand potential access and commercial opportunity in MPS II and MPS I Pivotal trial of RGX-202 for Duchenne Muscular Dystrophy progressing rapidly; enrollment...

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference PR Newswire ROCKVILLE, Md., March 10, 2025 ROCKVILLE, Md. , March 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced new interim biomarker data from the Phase I/II portion of the AFFINITY DUCHENNE ® trial of RGX-202 for the treatment of Duchenne muscular dystrophy will be presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific...

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases PR Newswire ROCKVILLE, Md., March 4, 2025 ROCKVILLE, Md. , March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, REGENXBIO and Nippon Shinyaku will develop and commercialize RGX-121 ( clemidsogene lanparvovec) for Mucopolysaccharidosis II (MPS II), also known as Hunter...

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights PR Newswire ROCKVILLE, Md., Feb. 26, 2025 ROCKVILLE, Md. , Feb. 26, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13 , at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2024 , and recent operational highlights. Listeners can...

REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Feb. 25, 2025 ROCKVILLE, Md. , Feb. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: TD Cowen's 45th Annual Health Care Conference Fireside Chat: Wednesday, March 5 at 1:10pm ET Location: Boston, MA Leerink Partners Global Healthcare Conference Fireside Chat: Tuesday, March 11 at 9:20am ET Location: Miami, FL Barclays 27 th Annual...

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE, Md., Jan. 30, 2025 ROCKVILLE, Md. , Jan. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 21 st Annual WORLD Symposium ™ 2025, taking place in San Diego, CA February 3-7, 2025 . The following...

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases PR Newswire ROCKVILLE, Md., Jan. 14, 2025 REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in U.S. and...